Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Melanoma and chronic exposure to contraceptives containing microdoses of ethinylestradiol in young women: a retrospective study from the Research on Adverse Drug Events and Reports (RADAR) project comprising a large Midwestern U.S. patient population

Melanoma and chronic exposure to contraceptives containing microdoses of ethinylestradiol in... Dear EditorAn association between the use of contraceptives containing exogenous oestrogen compounds and subsequent diagnosis for malignant melanoma (MM) has been suspected for decades. This is, in part, due to the finding that oestrogen stimulates melanogenesis and the observation that the incidence of MM is greater in women vs. men before the age of 50, but lower than in men after the age of 50, corresponding with the average age of menopause when oestrogen levels dramatically decrease.Prior studies assessing the relationship between the incidence of MM and exposure to exogenous oestrogen provide conflicting results. Moreover, the vast majority of previous reports do not specify the oestrogen‐based dosage form, nor the actual dose of the oestrogenic compound, and typically rely on patient completed questionnaires that are subject to recall bias. Further, over recent decades, the dosage of oestrogenic compounds in hormonal contraceptives has greatly decreased compared to studies of the earliest oestrogenic compounds where an association with MM was reported. Given widespread and chronic use, the aim of this study was to determine whether exposure to contraceptives containing ethinylestradiol (EE) at microdoses (40mcg/day or less) showed an association with MM within a large, urban, Midwestern U.S. patient population served by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Melanoma and chronic exposure to contraceptives containing microdoses of ethinylestradiol in young women: a retrospective study from the Research on Adverse Drug Events and Reports (RADAR) project comprising a large Midwestern U.S. patient population

Download PDF
2 pages

Loading next page...
 
/lp/wiley/melanoma-and-chronic-exposure-to-contraceptives-containing-microdoses-HSt00PJsdh

References (10)

Publisher
Wiley
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
DOI
10.1111/jdv.14534
Publisher site
See Article on Publisher Site

Abstract

Dear EditorAn association between the use of contraceptives containing exogenous oestrogen compounds and subsequent diagnosis for malignant melanoma (MM) has been suspected for decades. This is, in part, due to the finding that oestrogen stimulates melanogenesis and the observation that the incidence of MM is greater in women vs. men before the age of 50, but lower than in men after the age of 50, corresponding with the average age of menopause when oestrogen levels dramatically decrease.Prior studies assessing the relationship between the incidence of MM and exposure to exogenous oestrogen provide conflicting results. Moreover, the vast majority of previous reports do not specify the oestrogen‐based dosage form, nor the actual dose of the oestrogenic compound, and typically rely on patient completed questionnaires that are subject to recall bias. Further, over recent decades, the dosage of oestrogenic compounds in hormonal contraceptives has greatly decreased compared to studies of the earliest oestrogenic compounds where an association with MM was reported. Given widespread and chronic use, the aim of this study was to determine whether exposure to contraceptives containing ethinylestradiol (EE) at microdoses (40mcg/day or less) showed an association with MM within a large, urban, Midwestern U.S. patient population served by

Journal

Journal of the European Academy of Dermatology & Venereology – Wiley

Published: Jan 1, 2018

There are no references for this article.